Alpha Tau Medical (NASDAQ:DRTS) Lowered to “Sell” at Zacks Investment Research

Alpha Tau Medical (NASDAQ:DRTSGet Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday, Zacks.com reports.

According to Zacks, “Alpha Tau Medical Ltd. is a medical device company. It focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. Alpha Tau Medical Ltd., formerly known as Healthcare Capital Corp., is based in JERUSALEM. “

Several other equities analysts also recently issued reports on DRTS. Cantor Fitzgerald assumed coverage on shares of Alpha Tau Medical in a research note on Thursday, April 14th. They set an “overweight” rating and a $20.00 price target for the company. Piper Sandler assumed coverage on shares of Alpha Tau Medical in a research note on Friday, April 8th. They set an “overweight” rating and a $19.00 price target for the company. Finally, Citigroup initiated coverage on shares of Alpha Tau Medical in a research note on Monday, April 4th. They set a “buy” rating and a $21.00 price target for the company.

Shares of DRTS stock traded up $1.26 during trading hours on Thursday, hitting $10.17. 517,958 shares of the company’s stock traded hands, compared to its average volume of 976,472. Alpha Tau Medical has a 12 month low of $8.27 and a 12 month high of $20.65.

About Alpha Tau Medical (Get Rating)

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, lung, and prostate cancers.

See Also

Get a free copy of the Zacks research report on Alpha Tau Medical (DRTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.